San Diego-dependent Viking Therapeutics marked itself as a serious competitor inside the weight loss drug marketplace in February soon after revealing promising details from the mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided like a weekly injection and in March the c